Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul;31(7):961-982.
doi: 10.1136/ijgc-2021-002565. Epub 2021 Jun 10.

ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors

Dirk Timmerman  1   2 , François Planchamp  3 , Tom Bourne  4   2   5 , Chiara Landolfo  6 , Andreas du Bois  7 , Luis Chiva  8 , David Cibula  9 , Nicole Concin  7   10 , Daniela Fischerova  9 , Wouter Froyman  4 , Guillermo Gallardo Madueño  11 , Birthe Lemley  12   13 , Annika Loft  14 , Liliana Mereu  15 , Philippe Morice  16 , Denis Querleu  17   18 , Antonia Carla Testa  6   19 , Ignace Vergote  20 , Vincent Vandecaveye  21   22 , Giovanni Scambia  6   19 , Christina Fotopoulou  23
Affiliations
Review

ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors

Dirk Timmerman et al. Int J Gynecol Cancer. 2021 Jul.

Abstract

The European Society of Gynaecological Oncology (ESGO), the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG), the International Ovarian Tumour Analysis (IOTA) group, and the European Society for Gynaecological Endoscopy (ESGE) jointly developed clinically relevant and evidence-based statements on the pre-operative diagnosis of ovarian tumors, including imaging techniques, biomarkers, and prediction models. ESGO/ISUOG/IOTA/ESGE nominated a multidisciplinary international group, including expert practising clinicians and researchers who have demonstrated leadership and expertise in the pre-operative diagnosis of ovarian tumors and management of patients with ovarian cancer (19 experts across Europe). A patient representative was also included in the group. To ensure that the statements were evidence-based, the current literature was reviewed and critically appraised. Preliminary statements were drafted based on the review of the relevant literature. During a conference call, the whole group discussed each preliminary statement and a first round of voting was carried out. Statements were removed when a consensus among group members was not obtained. The voters had the opportunity to provide comments/suggestions with their votes. The statements were then revised accordingly. Another round of voting was carried out according to the same rules to allow the whole group to evaluate the revised version of the statements. The group achieved consensus on 18 statements. This Consensus Statement presents these ESGO/ISUOG/IOTA/ESGE statements on the pre-operative diagnosis of ovarian tumors and the assessment of carcinomatosis, together with a summary of the evidence supporting each statement.

Keywords: ovarian neoplasms; ovary.

PubMed Disclaimer

Conflict of interest statement

Competing interests: DT: senior investigator FWO (Fund for Scientific Research Flanders), and research sponsored by Roche Diagnostics. KU Leuven has consultancy agreements with GE Healthcare, Samsung Healthcare, GSK, and Canon. TB: research sponsored by Roche Diagnostics, Samsung Medison and Illumina, and grants for traveling from Samsung Medison. LC: advisory boards for AstraZeneca, GSK, Takeda, and Roche. DC: advisory boards for Genmab, AstraZeneca, Roche, and Sotio. NC: advisory boards for AstraZeneca, Seattle Genetics, Mersana and eTheRNA Immunotherapies NV, grants for traveling from Roche, Genmab and Amgen, and educational fees from MSD and Medscape Oncology. AdB: advisory boards for Roche, AstraZeneca, GSK/Tesaro, BIOCAD, Clovis, Genmab/Seattle Genetics, Pfizer, and Amgen, and grants for traveling from Roche and AstraZeneca. IV: consulting activities for Amgen, AstraZeneca, Clovis Oncology, Carrick Therapeutics, Debiopharm International SA, Deciphera Pharmaceuticals, Elevar Therapeutics, F Hoffmann-La Roche Ltd, Genmab, GSK, Immunogen Inc, Medical University of Vienna, Mersana, Millenium Pharmaceuticals, MSD, Novocure, Octimet Oncology NV, Oncoinvent AS, Pharmamar, Sotioa.s, Tesaro Inc, Verastem Oncology, and Zentalis, contracted research (via KU Leuven) from Oncoinvent AS and Genmab, grants (corporate sponsored research) from Amgen and Roche, and accommodations/travel expenses from Amgen, MSD, Tesaro, AstraZeneca, and Roche. CF: advisory boards for Roche, GSK, Tesaro, AZ/MSD, Clovis, Sequana and Ethicon, and grants for traveling from GSK and Roche. FP, CL, DF, WF, GG, BL, AL, LM, PM, DQ, ACT, VV and GS: no conflicts of interest.

Figures

Figure 1
Figure 1
Eight-step process for development of the Consensus Statement on the pre-operative diagnosis of ovarian tumors and assessment of disease spread.
Figure 2
Figure 2
Flowchart of steps recommended to distinguish between benign and malignant tumors and to direct patients towards appropriate treatment pathway. CT, computed tomography; F/U, follow-up; IOTA ADNEX, International Ovarian Tumour Analysis Group Assessment of Different NEoplasias in the adneXa; MRI, magnetic resonance imaging; O-RADS, Ovarian-Adnexal Reporting and data system.
Figure 3
Figure 3
Flowchart of steps necessary to differentiate between subgroups of malignancy and extent of disease within gynecological oncology centers. *Early stage and advanced stage might differ according to different ADNEX models (stage I vs stages III–IV) and oncologically (stages I–II vs stages I–IV). αFP, alpha-fetoprotein; AMH, anti-Müllerian hormone; CA 125, cancer antigen 125; CA 15-3, cancer antigen 15-3; CA 19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CT, computed tomography; hCG, human chorionic gonadoptropin; IOTA ADNEX, International Ovarian Tumor Analysis group Assessment of Different NEoplasias in the adneXa; LDH, lactate dehydrogenase; MRI, magnetic resonance imaging; PET-CT, positron emission tomography-computed tomography.
See this image and copyright information in PMC

Comment in

References

    1. Querleu D, Planchamp F, Chiva L, et al. . European Society of Gynaecological Oncology (ESGO) guidelines for ovarian cancer surgery. Int J Gynecol Cancer 2017;27:1534–42. 10.1097/IGC.0000000000001041 - DOI - PubMed
    1. Woo YL, Kyrgiou M, Bryant A, et al. . Centralisation of services for gynaecological cancer. Cochrane Database Syst Rev 2012;4. 10.1002/14651858.CD007945.pub2 - DOI - PMC - PubMed
    1. Engelen MJA, Kos HE, Willemse PHB, et al. . Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer 2006;106:589–98. 10.1002/cncr.21616 - DOI - PubMed
    1. Froyman W, Landolfo C, De Cock B, et al. . Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort study. Lancet Oncol 2019;20:448–58. 10.1016/S1470-2045(18)30837-4 - DOI - PubMed
    1. du Bois A, Rochon J, Pfisterer J, et al. . Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review. Gynecol Oncol 2009;112:422–36. 10.1016/j.ygyno.2008.09.036 - DOI - PubMed

Publication types